Advanced search×

Discovery and characterization of cnidarian peptide toxins that affect neuronal potassium ion channels

Toxicon 54(8):6 (2009) PMID 19269305

Peptides have been isolated from several species of sea anemones and shown to block currents through various potassium ion channels, particularly in excitable cells. The toxins can be grouped into four structural classes: type 1 with 35-37 amino acid residues and three disulphide bridges; type 2 with 58-59 residues and three disulphide bridges; type 3 with 41-42 residues and three disulphide bridges; and type 4 with 28 residues and two disulphide bridges. Examples from the first class are BgK from Bunodosoma granulifera, ShK from Stichodactyla helianthus and AsKS (or kaliseptine) from Anemonia sulcata (now A. viridis). These interfere with binding of radiolabelled dendrotoxin to synaptosomal membranes and block currents through channels with various Kv1 subunits and also intermediate conductance K(Ca) channels. Toxins in the second class are homologous to Kunitz-type inhibitors of serine proteases; these toxins include kalicludines (AsKC 1-3) from A. sulcata and SHTXIII from S. haddoni; they block Kv1.2 channels. The third structural group includes BDS-I, BDS-II (from A. sulcata) and APETx 1 (from Anthropleura elegantissima). Their pharmacological specificity differs: BDS-I and -II block currents involving Kv3 subunits, while APETx1 blocks ERG channels. The fourth group comprises the more recently discovered SHTX I and II from S. haddoni. Their channel blocking specificity is not yet known but they displace dendrotoxin binding from synaptosomal membranes. Sea anemones can be predicted to be a continued source of new toxins that will serve as molecular probes of various K^+ channels.

DOI: 10.1016/j.toxicon.2009.02.032
Version: za2963e q8za5 q8zb6 q8zcc q8zde q8ze4 q8zf3 q8zg5

Similar articles you may find interesting…

  1. Current and emerging strategies for treating hepatic encephalopathy.

    Crit Care Nurs Clin North Am 22(3):341-50 (2010) PMID 20691385

    Hepatic encephalopathy (HE) is caused by liver impairment and has a multitude of symptoms in affected patients, including change in level of consciousness, intellectual function, and neuromuscular function. Pharmacologic therapy includes use of nonabsorbable disaccharides (lactulose and lactitol), a...
  2. Ursodeoxycholic acid in the prevention of gallstone formation after bariatric surgery: a meta-analysis.

    Obes Surg 18(12):1532-8 (2008) PMID 18574646

    Rapid weight loss increases risk for gallstone formation. Prophylactic cholecystectomy is difficult. Several small trials have shown that ursodeoxycholic acid (UDCA) may prevent gallstone formation after bariatric surgery. The aim of this study is to assess the efficacy and safety of...
  3. Measuring symptoms in the irritable bowel syndrome: development of a framework for clinical trials.

    Audio, Transactions of the IRE Professi... 32(10):1275-91 (2010) PMID 20955447

    We applied FDA guidance to develop a framework that can serve as the foundation for developing a PRO for IBS clinical trials. © 2010 Blackwell Publishing Ltd....